Results for tag: "Self Amplifying RNA Vaccines"

Self-amplifying RNA vaccines (saRNA) are a subcategory within the broader realm of RNA-based immunizations. These vaccines employ a construct that contains the RNA sequence for a pathogen's antigen as well as elements that enable the RNA to replicate within host cells. This replication amplifies the initial signal, potentially leading to a robust immune response at lower doses compared to conventional mRNA vaccines. The technology merges the advantages of viral vector vaccines and non-replicating mRNA vaccines, aiming to provoke a strong immune response while maintaining a good safety profile and temperature stability. Development of saRNA vaccines has been accelerated through advancements in lipid nanoparticle delivery systems and molecular engineering, which enhance the stability and efficacy of the RNA. These vaccines are seen as a promising approach for a range of infectious diseases and possibly for cancer immunotherapy, given their ability to present antigens and stimulate both the humoral and cellular arms of the immune system. Companies active in the self-amplifying RNA vaccines market include Moderna, BioNTech, Arcturus Therapeutics, CureVac, and Imperial College London, among others. Their efforts are directed toward research, development, and, in some cases, the commercialization of saRNA vaccine candidates for various therapeutic applications. Show Less Read more